Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantern PharmaLTRN -0.34%33 Market Cap is $38.02 Mil as of Jul. 21, 2026. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Lantern Pharma ranks worse than 67.11% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lantern Pharma's share price for the quarter that ended in Mar. 2026 was $1.37. Lantern Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 11.26 Mil. Therefore, Lantern Pharma's market cap for the quarter that ended in Mar. 2026 was $15.42 Mil.
Lantern Pharma's quarterly market cap
declined
from Sep. 2025 ($48.02 Mil) to Dec. 2025 ($34.10 Mil) and
declined
from Dec. 2025 ($34.10 Mil) to Mar. 2026 ($15.42 Mil).
Lantern Pharma's annual market cap
declined
from Dec. 2023 ($45.89 Mil) to Dec. 2024 ($34.40 Mil) and
declined
from Dec. 2024 ($34.40 Mil) to Dec. 2025 ($34.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lantern Pharma's Enterprise Value for Today is $31.25 Mil.
Lantern Pharma (NAS:LTRN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lantern Pharma Market Cap Related Terms
Lantern Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Lantern Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lantern Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lantern Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantern Pharma (LTRN) has a Market Cap of $38.02 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lantern Pharma and its competitors. According to the industry distribution chart, Lantern Pharma ranks #955 out of 1423 companies in the Biotechnology industry, placing it in the top 67.1%.
Is Lantern Pharma's Market Cap too high?
Lantern Pharma's current Market Cap is $38.02 Mil. The Biotechnology industry median Market Cap is 111.61. Lantern Pharma's value of $38.02 Mil is 65.9% below this industry median. Based on the distribution chart, Lantern Pharma ranks #955 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's Market Cap compare to PDSB and AURX?
According to the Biotechnology industry distribution chart, Lantern Pharma ranks #955 out of 1423 companies for Market Cap. This places Lantern Pharma in the lower half of its industry. The industry median Market Cap is 111.61. Lantern Pharma's value of $38.02 Mil is 65.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantern Pharma's current Market Cap of $38.02 Mil is 65.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lantern Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantern Pharma's current Market Cap is $38.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current Market Cap of $38.02 Mil. The current Market Cap is $38.02 Mil and 65.9% below the Biotechnology industry median of 111.61. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current Market Cap is $38.02 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score
Get the complete analysis for LTRN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTRN has been successfully added to your 
